300357 我武生物
已收盘 01-13 15:00:00
资讯
新帖
简况
我武生物涨6.14%，西南证券二个月前给出“买入”评级
证券之星 · 01-05
我武生物涨6.14%，西南证券二个月前给出“买入”评级
创新药概念大幅拉升，我武生物涨超6%
证券之星 · 01-05
创新药概念大幅拉升，我武生物涨超6%
我武生物最新公告：获得豚草花粉点刺液药物临床试验补充申请批准通知书
证券之星 · 2025-11-21
我武生物最新公告：获得豚草花粉点刺液药物临床试验补充申请批准通知书
我武生物(300357.SZ)：终止烟曲霉点刺液研发项目
智通财经 · 2025-11-14
我武生物(300357.SZ)：终止烟曲霉点刺液研发项目
股市必读：我武生物（300357）10月30日董秘有最新回复
证券之星 · 2025-10-31
股市必读：我武生物（300357）10月30日董秘有最新回复
我武生物：异体间充质干细胞治疗药物处在临床前研究阶段
证券之星 · 2025-10-30
我武生物：异体间充质干细胞治疗药物处在临床前研究阶段
脱敏龙头我武生物盈利质量跃升，三季报多项核心数据亮眼，研发驱动构筑成长新范式
证券之星 · 2025-10-24
脱敏龙头我武生物盈利质量跃升，三季报多项核心数据亮眼，研发驱动构筑成长新范式
我武生物(300357.SZ)发布前三季度业绩，归母净利润3.45亿元，增长26.67%
智通财经 · 2025-10-23
我武生物(300357.SZ)发布前三季度业绩，归母净利润3.45亿元，增长26.67%
消息面利好叠加基本面稳健，我武生物股价大涨超10%
证券之星 · 2025-10-20
消息面利好叠加基本面稳健，我武生物股价大涨超10%
股市必读：我武生物（300357）10月10日董秘有最新回复
证券之星 · 2025-10-13
股市必读：我武生物（300357）10月10日董秘有最新回复
我武生物：专注国内市场暂无出海计划
证券之星 · 2025-10-10
我武生物：专注国内市场暂无出海计划
股市必读：我武生物（300357）9月30日董秘有最新回复
证券之星 · 2025-10-09
股市必读：我武生物（300357）9月30日董秘有最新回复
我武生物(300357.SZ)取得烟曲霉点刺液I期临床试验总结报告
智通财经 · 2025-09-25
我武生物(300357.SZ)取得烟曲霉点刺液I期临床试验总结报告
海通国际：上调我武生物目标价至37.05元，给予增持评级
证券之星 · 2025-09-12
海通国际：上调我武生物目标价至37.05元，给予增持评级
我武生物：粉尘螨滴剂适应症为粉尘螨过敏引起的过敏性鼻炎、过敏性哮喘
证券之星 · 2025-09-08
我武生物：粉尘螨滴剂适应症为粉尘螨过敏引起的过敏性鼻炎、过敏性哮喘
股市必读：我武生物（300357）9月5日董秘有最新回复
证券之星 · 2025-09-08
股市必读：我武生物（300357）9月5日董秘有最新回复
我武生物：公司研发人员可以借助DeepSeek等大语言模型检索相关研发信息和资料
证券之星 · 2025-09-05
我武生物：公司研发人员可以借助DeepSeek等大语言模型检索相关研发信息和资料
【机构调研记录】民生加银基金调研我武生物、金盘科技等6只个股（附名单）
证券之星 · 2025-09-02
【机构调研记录】民生加银基金调研我武生物、金盘科技等6只个股（附名单）
半年报预增板块大涨，我武生物上涨超10%
证券之星 · 2025-08-27
半年报预增板块大涨，我武生物上涨超10%
核心产品矩阵协同发力，我武生物中报营利双位数增长，持续扩容研发管线为长期增长奠基
证券之星 · 2025-08-22
核心产品矩阵协同发力，我武生物中报营利双位数增长，持续扩容研发管线为长期增长奠基
加载更多
公司概况
公司名称：
浙江我武生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2014-01-21
主营业务：
浙江我武生物科技股份有限公司的主营业务是过敏性疾病诊断及治疗产品的研发、生产和销售。公司的主要产品是粉尘螨滴剂（国药准字S20060012，商品名：畅迪）、黄花蒿花粉变应原舌下滴剂（国药准字S20210001，商品名：畅皓）、以及粉尘螨皮肤点刺诊断试剂盒（国药准字S20080010，商品名：畅点）。
发行价格：
20.05
{"stockData":{"symbol":"300357","market":"SZ","secType":"STK","nameCN":"我武生物","latestPrice":31.26,"timestamp":1768287819000,"preClose":30.85,"halted":0,"volume":9805504,"delay":0,"changeRate":0.0133,"floatShares":484000000,"shares":524000000,"eps":0.7457,"marketStatus":"已收盘","change":0.41,"latestTime":"01-13 15:00:00","open":31.1,"high":32.11,"low":31.03,"amount":309000000,"amplitude":0.035,"askPrice":31.27,"askSize":66,"bidPrice":31.26,"bidSize":58,"shortable":0,"etf":0,"ttmEps":0.7457,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1768354200000},"marketStatusCode":5,"adr":0,"adjPreClose":30.85,"symbolType":"stock","openAndCloseTimeList":[[1768267800000,1768275000000],[1768280400000,1768287600000]],"highLimit":33.94,"lowLimit":27.77,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":523584000,"isCdr":false,"pbRate":6.13,"roa":"--","peRate":41.920343,"roe":"13.8%","epsLYR":0.607,"committee":0.092971,"marketValue":16367000000,"turnoverRate":0.0203,"status":0,"floatMarketCap":15132000000},"requestUrl":"/m/hq/s/300357","defaultTab":"news","newsList":[{"id":"2601510006","title":"我武生物涨6.14%，西南证券二个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2601510006","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601510006?lang=zh_cn&edition=full","pubTime":"2026-01-05 15:44","pubTimestamp":1767599089,"startTime":"0","endTime":"0","summary":"今日我武生物涨6.14%，收盘报30.09元。2025年10月27日，西南证券研究员杜向阳发布了对我武生物的研报《2025年三季报点评：核心产品稳健增长，在研管线持续拓展》，该研报对我武生物给出“买入”评级。研报中预计2025-2027年净利润分别为3.9亿元、4.7亿元、5.7亿元，对应动态PE分别为45倍、37倍、30倍，维持“买入”评级。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信证券的王凯旋、陈竹、韩世通。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500015778.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357","600369"],"gpt_icon":0},{"id":"2601705280","title":"创新药概念大幅拉升，我武生物涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601705280","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601705280?lang=zh_cn&edition=full","pubTime":"2026-01-05 13:49","pubTimestamp":1767592183,"startTime":"0","endTime":"0","summary":"1月5日，A股创新药概念大幅走高，相关概念股普遍上涨，其中我武生物盘中一度涨超6%。消息面上，国家药监局数据显示，2025年我国已批准上市的创新药达76个，大幅超过2024年全年48个，创历史新高。2025年前三季度，我武生物营收与净利润均实现稳健增长。其中，“粉尘螨滴剂”作为基本盘贡献7.94亿元收入，同比增长13.38%；而“黄花蒿花粉变应原舌下滴剂”与“皮肤点刺液”两大产品线得益于市场推广加码，收入增速均超90%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026010500014527.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0028","06978","300357","BK1161","BK0239","159992"],"gpt_icon":0},{"id":"2585811111","title":"我武生物最新公告：获得豚草花粉点刺液药物临床试验补充申请批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2585811111","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585811111?lang=zh_cn&edition=full","pubTime":"2025-11-21 18:10","pubTimestamp":1763719854,"startTime":"0","endTime":"0","summary":"我武生物公告称，公司提交的“豚草花粉点刺液”药物临床试验补充申请获得批准。该药品注册申请人为我武生物，注册分类为治疗用生物制品，剂型为皮肤点刺试剂，适应症为用于皮肤点刺试验，辅助诊断与豚草花粉致敏相关的I型变态反应性疾病。公司将根据进展情况及时履行信息披露义务。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100028343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2583457545","title":"我武生物(300357.SZ)：终止烟曲霉点刺液研发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2583457545","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583457545?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:44","pubTimestamp":1763109882,"startTime":"0","endTime":"0","summary":"智通财经APP讯，我武生物(300357.SZ)发布公告，日前，公司管理层对烟曲霉点刺液研发项目进行了审慎评估，综合项目进展情况、继续开发的风险等多种因素，为合理配置公司研发资源，聚焦研发管线中的优势项目，公司决定终止烟曲霉点刺液研发项目，不再开展后续的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369329.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","300357","BK0239"],"gpt_icon":0},{"id":"2579107343","title":"股市必读：我武生物（300357）10月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2579107343","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579107343?lang=zh_cn&edition=full","pubTime":"2025-10-31 07:57","pubTimestamp":1761868631,"startTime":"0","endTime":"0","summary":"截至2025年10月30日收盘，我武生物报收于33.7元，下跌2.66%，换手率2.14%，成交量10.35万手，成交额3.51亿元。董秘最新回复投资者： 请问贵司干细胞研究的进展如何了？日本已经大量应用于临床了。当日关注点来自交易信息汇总：10月30日主力资金净流出687.72万元，游资资金净流入777.34万元。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100011034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"gpt_icon":0},{"id":"2579948161","title":"我武生物：异体间充质干细胞治疗药物处在临床前研究阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2579948161","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579948161?lang=zh_cn&edition=full","pubTime":"2025-10-30 16:15","pubTimestamp":1761812136,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物10月30日在投资者关系平台上答复投资者关心的问题。请问贵司的异体间充质干细胞治疗药物能带到多大的市场预期？在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000029316.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2577591836","title":"脱敏龙头我武生物盈利质量跃升，三季报多项核心数据亮眼，研发驱动构筑成长新范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2577591836","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577591836?lang=zh_cn&edition=full","pubTime":"2025-10-24 17:23","pubTimestamp":1761297826,"startTime":"0","endTime":"0","summary":"证券之星注意到，这份“利润增速高于营收”的优质成绩单，源于我武生物主导产品的稳定增长与新产品的快速放量，更得益于其“研发驱动”的鲜明战略。在我国脱敏治疗市场，我武生物具备领先地位。单季度业绩逐季增长，表明我武生物盈利能力显著提升。截至2025年三季度末，我武生物的经营活动产生的现金流量净额达2.87亿元，同比大幅增长79.11%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025102400031338.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2577130622","title":"我武生物(300357.SZ)发布前三季度业绩，归母净利润3.45亿元，增长26.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2577130622","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2577130622?lang=zh_cn&edition=full","pubTime":"2025-10-23 19:37","pubTimestamp":1761219453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，我武生物(300357.SZ)发布2025年三季度报告，该公司前三季度营业收入为8.53亿元，同比增长16.86%。归属于上市公司股东的净利润为3.45亿元，同比增长26.67%。归属于上市公司股东的扣除非经常性损益的净利润为3.4亿元，同比增长28.92%。基本每股收益为0.6587元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1358893.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"我武生物(300357.SZ)发布前三季度业绩，归母净利润3.45亿元，增长26.67%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300357"],"gpt_icon":0},{"id":"2576365768","title":"消息面利好叠加基本面稳健，我武生物股价大涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2576365768","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2576365768?lang=zh_cn&edition=full","pubTime":"2025-10-20 15:40","pubTimestamp":1760946020,"startTime":"0","endTime":"0","summary":"10月20日，创新药概念股集体大涨，其中我武生物股价股价涨幅达10.07%，成交额达7.37亿元。从业绩基本面看，我武生物维持稳健增长态势。2025年半年报显示，公司营业收入为4.84亿元，同比上升12.81%；归母净利润为1.77亿元，同比上升18.61%；扣非归母净利润为1.73亿元，同比上升21.97%。海通国际证券指出公司核心品种粉尘螨滴剂稳步增长，新产品黄花蒿粉滴剂快速放量，点刺液产品不断丰富，研发领域也有多项进展，维持增持评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025102000015079.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"gpt_icon":0},{"id":"2575485414","title":"股市必读：我武生物（300357）10月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2575485414","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575485414?lang=zh_cn&edition=full","pubTime":"2025-10-13 02:53","pubTimestamp":1760295189,"startTime":"0","endTime":"0","summary":"截至2025年10月10日收盘，我武生物报收于29.42元，上涨1.94%，换手率2.74%，成交量13.28万手，成交额3.95亿元。公司产品黄花蒿花粉变应原舌下滴剂与皮肤点刺液产品三季度的销售情况请关注公司后续披露的2025年第三季度报告。当日关注点来自交易信息汇总：10月10日主力资金净流入1280.18万元，游资资金净流入3492.09万元，散户资金净流出4772.26万元。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101300000970.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","300357","BK0239"],"gpt_icon":0},{"id":"2574128790","title":"我武生物：专注国内市场暂无出海计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2574128790","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574128790?lang=zh_cn&edition=full","pubTime":"2025-10-10 16:01","pubTimestamp":1760083269,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物10月10日在投资者关系平台上答复投资者关心的问题。黄花蒿和皮肤点刺34季度销售展望如何，我武生物回复：投资者您好，在变应原制品领域，目前公司专注国内市场。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101000023050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2574976460","title":"股市必读：我武生物（300357）9月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2574976460","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2574976460?lang=zh_cn&edition=full","pubTime":"2025-10-09 01:57","pubTimestamp":1759946231,"startTime":"0","endTime":"0","summary":"截至2025年9月30日收盘，我武生物报收于29.19元，上涨2.24%，换手率2.16%，成交量10.44万手，成交额3.05亿元。董秘最新回复投资者： 董秘你好！交易信息汇总资金流向9月30日主力资金净流入1849.2万元，占总成交额6.06%；游资资金净流入3459.83万元，占总成交额11.34%；散户资金净流出5309.03万元，占总成交额17.4%。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025100900000594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","300357"],"gpt_icon":0},{"id":"2570064267","title":"我武生物(300357.SZ)取得烟曲霉点刺液I期临床试验总结报告","url":"https://stock-news.laohu8.com/highlight/detail?id=2570064267","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570064267?lang=zh_cn&edition=full","pubTime":"2025-09-25 16:31","pubTimestamp":1758789065,"startTime":"0","endTime":"0","summary":"智通财经APP讯，我武生物 ，公司研发的“烟曲霉点刺液”完成了“一项在中国志愿者中探索烟曲霉点刺液安全性及有效性的临床研究——单中心、开放的I期临床研究”，并取得了I期临床试验总结报告。烟曲霉点刺液在设定的剂量范围内具有良好的安全性，发生的不良事件均为1级或2级，未发生严重不良反应或导致退出的不良事件。在受试者中出现一定比例的迟发反应，提示可能与烟曲霉属于真菌的特性有关。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1349334.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2566947900","title":"海通国际：上调我武生物目标价至37.05元，给予增持评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2566947900","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2566947900?lang=zh_cn&edition=full","pubTime":"2025-09-12 12:25","pubTimestamp":1757651124,"startTime":"0","endTime":"0","summary":"海通国际证券集团有限公司Kehan Meng,Wenxin Yu,Ping Peng近期对我武生物进行研究并发布了研究报告《我武生物2025年中报点评：粉尘螨业绩稳步恢复，黄花蒿销售取得突破》，上调我武生物目标价至37.05元，给予增持评级。 我武生物 本报告导读： 公司核心品种粉尘螨滴剂稳步增长，新产品黄花蒿粉滴剂快速放量，点刺液产品不断丰富，研发领域也有多项进展，维持增持评级。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091200016358.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357"],"gpt_icon":0},{"id":"2565149501","title":"我武生物：粉尘螨滴剂适应症为粉尘螨过敏引起的过敏性鼻炎、过敏性哮喘","url":"https://stock-news.laohu8.com/highlight/detail?id=2565149501","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565149501?lang=zh_cn&edition=full","pubTime":"2025-09-08 16:30","pubTimestamp":1757320248,"startTime":"0","endTime":"0","summary":"我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090800020790.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2565524562","title":"股市必读：我武生物（300357）9月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2565524562","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565524562?lang=zh_cn&edition=full","pubTime":"2025-09-08 02:25","pubTimestamp":1757269515,"startTime":"0","endTime":"0","summary":"截至2025年9月5日收盘，我武生物报收于32.48元，上涨1.4%，换手率3.08%，成交量14.93万手，成交额4.79亿元。当日关注点来自交易信息汇总：9月5日主力资金净流入1268.05万元，显示主力对个股短期态度偏积极。我武生物长期深耕过敏性疾病诊疗领域，依托自主研发能力，推出脱敏治疗产品：\"粉尘螨滴剂\"与 \"黄花蒿花粉变应原舌下滴剂\"。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090800000651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300357","BK0028"],"gpt_icon":0},{"id":"2565556804","title":"我武生物：公司研发人员可以借助DeepSeek等大语言模型检索相关研发信息和资料","url":"https://stock-news.laohu8.com/highlight/detail?id=2565556804","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2565556804?lang=zh_cn&edition=full","pubTime":"2025-09-05 17:18","pubTimestamp":1757063890,"startTime":"0","endTime":"0","summary":"证券之星消息，我武生物09月05日在投资者关系平台上答复投资者关心的问题。在我国北方地区，蒿属花粉是夏秋季引发该疾病的主要气传过敏原。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090500028448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300357"],"gpt_icon":0},{"id":"2564582326","title":"【机构调研记录】民生加银基金调研我武生物、金盘科技等6只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2564582326","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564582326?lang=zh_cn&edition=full","pubTime":"2025-09-02 08:06","pubTimestamp":1756771600,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及9月1日披露的机构调研信息，民生加银基金近期对6家上市公司进行了调研，相关名单如下：1）我武生物 调研纪要：公司提拔年轻销售经理承担更多责任，销售管理更精细化。2）金盘科技 调研纪要：公司固态变压器首台样机已完成，将在数据中心试用并逐步推广至国际市场。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090200006267.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0224","BK0239","688676","BK0028","300357"],"gpt_icon":0},{"id":"2562818797","title":"半年报预增板块大涨，我武生物上涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562818797","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562818797?lang=zh_cn&edition=full","pubTime":"2025-08-27 14:40","pubTimestamp":1756276849,"startTime":"0","endTime":"0","summary":"8月27日，A股半年报预增概念股集体走强，我武生物盘中涨幅一度突破10%，截至发稿仍维持高位震荡，成交额达8.05亿元，换手率5.45%。作为国内变态反应原制品细分领域龙头，我武生物依托“粉尘螨滴剂”与“黄花蒿花粉滴剂”两大核心产品构建竞争壁垒。半年报显示，我武生物当前推进7个在研项目，技术迭代与品类扩展并举。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025082700025874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"gpt_icon":0},{"id":"2561479524","title":"核心产品矩阵协同发力，我武生物中报营利双位数增长，持续扩容研发管线为长期增长奠基","url":"https://stock-news.laohu8.com/highlight/detail?id=2561479524","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561479524?lang=zh_cn&edition=full","pubTime":"2025-08-22 19:33","pubTimestamp":1755862388,"startTime":"0","endTime":"0","summary":"在变态反应原制品这一细分领域，我武生物持续不断扩充研发管线，满足更多不同类型过敏性疾病患者的过敏原检测需求。今年上半年，我武生物产品粉尘螨滴剂销售收入为4.55.亿元，同比增长10.51%。今年上半年，我武生物主营业务毛利率增至95.37%，赚钱效应进一步提升。持续强化研发，丰富产品矩阵证券之星注意到，我武生物始终聚焦主业，深耕过敏性疾病诊疗领域。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2025082200039085.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","300357"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1768340769803,"stockEarnings":[{"period":"1week","weight":0.0317},{"period":"1month","weight":0.0423},{"period":"3month","weight":0.0199},{"period":"6month","weight":0.2385},{"period":"1year","weight":0.6767},{"period":"ytd","weight":0.1026}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0641},{"period":"3month","weight":0.0579},{"period":"6month","weight":0.1768},{"period":"1year","weight":0.3094},{"period":"ytd","weight":0.0428}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江我武生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"32427人(较上一季度减少6.22%)","perCapita":"14927股","listingDate":"2014-01-21","address":"浙江省湖州市德清县武康镇志远北路636号","registeredCapital":"52358万元","survey":" 浙江我武生物科技股份有限公司的主营业务是过敏性疾病诊断及治疗产品的研发、生产和销售。公司的主要产品是粉尘螨滴剂（国药准字S20060012，商品名：畅迪）、黄花蒿花粉变应原舌下滴剂（国药准字S20210001，商品名：畅皓）、以及粉尘螨皮肤点刺诊断试剂盒（国药准字S20080010，商品名：畅点）。","listedPrice":20.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"我武生物,300357,我武生物股票,我武生物股票老虎,我武生物股票老虎国际,我武生物行情,我武生物股票行情,我武生物股价,我武生物股市,我武生物股票价格,我武生物股票交易,我武生物股票购买,我武生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"我武生物(300357)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供我武生物(300357)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}